Mitochondrial haplogroups and cognitive progression in Parkinson’s disease

Ganqiang Liu(Sun Yat-sen University), Chunming Ni(Sun Yat-sen University), Jiamin Zhan(Sun Yat-sen University), Weimin Li(Sun Yat-sen University), Junfeng Luo(Sun Yat-sen University), Zhixiang Liao(Brigham and Women's Hospital), Joseph J. Locascio(Brigham and Women's Hospital), Wenbiao Xian(Sun Yat-sen University), Ling Chen(Sun Yat-sen University), Zhong Pei(Sun Yat-sen University), Jean‐Christophe Corvol(Inserm), Jodi Maple‐Grødem(Stavanger University Hospital), Meghan C. Campbell(Washington University in St. Louis), Alexis Elbaz(Inserm), Suzanne Lesage(Inserm), Alexis Brice(Inserm), Albert Y. Hung(Harvard University), Michael A. Schwarzschild(Harvard University), Michael T. Hayes(Brigham and Women's Hospital), Anne‐Marie Wills(Harvard University), Bernard Ravina(Praxis (United States)), Ira Shoulson(University of Rochester), Pille Taba(Tartu University Hospital), Sulev Kõks(Murdoch University), Thomas G. Beach(Banner Sun Health Research Institute), Florence Cormier‐Dequaire(Inserm), Guido Alves(Stavanger University Hospital), Ole‐Bjørn Tysnes(Haukeland University Hospital), Joel S. Perlmutter(Washington University in St. Louis), Peter Heutink(German Center for Neurodegenerative Diseases), Jacobus J. van Hilten(Leiden University Medical Center), Roger A. Barker(Wellcome/MRC Cambridge Stem Cell Institute), Caroline H. Williams‐Gray(University of Cambridge), Clemens R. Scherzer(Brigham and Women's Hospital), Ganqiang Liu(Sun Yat-sen University), Rebecca R. Valentino, Jiajie Peng, Zhixiang Liao(Brigham and Women's Hospital), Joseph J. Locascio(Brigham and Women's Hospital), Jean‐Christophe Corvol(Allen Institute for Brain Science), Xianjun Dong, Jodi Maple‐Grødem(Stavanger University Hospital), Meghan C. Campbell(Washington University in St. Louis), Alexis Elbaz(Inserm), Suzanne Lesage(Allen Institute for Brain Science), Alexis Brice(Allen Institute for Brain Science), Graziella Mangone, John H. Growdon, Albert Y. Hung(Harvard University), Michael A Schwarzchild(Brigham and Women's Hospital), Michael T. Hayes(Brigham and Women's Hospital), Anne‐Marie Wills(Harvard University), Todd M. Herrington, Bernard Ravian(Praxis (United States)), Ira Shoulson(University of Rochester), Pille Taba(Tartu University Hospital), Sulev Kõks(Murdoch University), Thomas G. Beach(Banner Sun Health Research Institute), Florence Cormier‐Dequaire(Allen Institute for Brain Science), Guido Alves(Stavanger University Hospital), Ole‐Bjørn Tysnes(Haukeland University Hospital), Joel S. Perlmutter(Washington University in St. Louis), Peter Heutink(German Center for Neurodegenerative Diseases), Jacobus J. van Hilten(Leiden University Medical Center), Meike Kasten, Brit Mollenhauer, Claudia Trenkwalder, Christine Klein, Roger A. Barker(Wellcome/MRC Cambridge Stem Cell Institute), Caroline H. Williams‐Gray(University of Cambridge), Johan Marinus, Clemens R. Scherzer(Brigham and Women's Hospital)
Brain
November 8, 2022
Cited by 24Open Access
Full Text

Abstract

Mitochondria are a culprit in the onset of Parkinson's disease, but their role during disease progression is unclear. Here we used Cox proportional hazards models to exam the effect of variation in the mitochondrial genome on longitudinal cognitive and motor progression over time in 4064 patients with Parkinson's disease. Mitochondrial macro-haplogroup was associated with reduced risk of cognitive disease progression in the discovery and replication population. In the combined analysis, patients with the super macro-haplogroup J, T, U# had a 41% lower risk of cognitive progression with P = 2.42 × 10-6 compared to those with macro-haplogroup H. Exploratory analysis indicated that the common mitochondrial DNA variant, m.2706A>G, was associated with slower cognitive decline with a hazard ratio of 0.68 (95% confidence interval 0.56-0.81) and P = 2.46 × 10-5. Mitochondrial haplogroups were not appreciably linked to motor progression. This initial genetic survival study of the mitochondrial genome suggests that mitochondrial haplogroups may be associated with the pace of cognitive progression in Parkinson's disease over time.


Related Papers

No related papers found

Powered by citation graph analysis